Idiopathic recurrent pericarditis: an up-to-date view of the problem
AbstractThe aim of this literature review is to summarize relevant data on the problem of etiology, pathogenesis and approaches to the treatment of idiopathic recurrent pericarditis (RP). The authors’ attention is focused on the pathogenetic aspects of RP associated with the involvement of innate immunity, as well as on the growing experience of using the main anti-interleukin‑1 drugs currently used to treat this pathology.
Material and methods. The literary review includes 138 articles published from 2006 to 2023 in English and Russian in scientific online libraries: PubMed (https://pubmed.ncbi.nlm.nih.gov/), SosgapeLibrary (https://www.cochranelibrary.com/), Oxford Medicine Online (https://academic.oup.com/), Springer (https://link.springer.com/), elibrary (https://www.elibrary.ru/defaultx.asp).
Results. Idiopathic recurrent pericarditis is based on autoimmune and auto-inflammatory processes. One of the main components of the autoinflammatory process is interleukin (IL)-1. Drugs that block the implementation of this pathway: anakinra, rhinolacept, cancinumab and goflicicept can be effectively used in the therapy of RP.
Conclusion. 5 lines of therapy are actively used for the RP treatment, including the appointment of nonsteroidal anti-inflammatory drugs, steroids, colchicine and azathioprine, anti-IL‑1 drugs and pericardiocentesis. Further research is needed to find effective combinations and minimally active doses of drugs in order to increase the effectiveness of therapy and reduce the risk of adverse events.
Keywords:idiopathic recurrent pericarditis; IL 1 inhibitor; goflicept; combination therapy
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Serezhina E.K., Obrezan A.G. Idiopathic recurrent pericarditis: an up-to-date view of the problem. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2024; 12 (1): 23–9. DOI: https://doi.org/10.33029/2309-1908-2024-12-1-23-29 (in Russian)
References
1. Adler Y., Charron P., Imazio M. et al. ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015; 36 (42): 2921–64. DOI: https://doi.org/10.1093/eurheartj/ehv318
2. Lopalco G., Rigante D., Cantarini L., et al. The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment. Trends Cardiovasc Med. 2021; 31 (5): 265–74.
3. Andreis A., Imazio M., Casula M., et al. Recurrent pericarditis: an update on diagnosis and management. Intern Emerg Med. 2021; 16 (3): 551–8.
4. Imazio M., Belli R., Brucato A., et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014; 383 (9936): 2232–7. DOI: https://doi.org/10.1016/S0140-6736(13)62709-9
5. Aldweib N., Farah V., Biederman R.W.W. Clinical Utility of Cardiac Magnetic Resonance Imaging in Pericardial Diseases. Curr Cardiol Rev. 2018; 14 (3): 200–12.
6. Imazio M., Pivetta E., Palacio Restrepo S., et al. Usefulness of cardiac magnetic resonance for recurrent pericarditis. Am J Cardiol. 2020; 125: 146–51.
7. Cremer P.C., Kumar A., Kontzias A., et al. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016; (68): 2311–28. DOI: https://doi.org/10.1016/j.jacc.2016.07.785
8. Cosyns B., Plein S., Nihoyanopoulos P., et al. European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging. 2015; (16): 12–31.
9. Markel G., Imazio M., Koren-Morag N., Galore-Haskel G., Schachter J., Besser M., et al. CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis. Oncotarget. 2016; 7 (14): 17885–95.
10. Soler-Soler J., Sagristà-Sauleda J., Permanyer-Miralda G. Relapsing pericarditis. Heart. 2004; 90 (11): 1364–8.
11. Daëron M. The immune system as a system of relations. Front Immunol. 2022; 13 (13): 984678.
12. Swanson K.V., Deng M., Ting J.P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019; (19): 477–89.
13. van Kempen T.S., Wenink M.H., Leijten E.F., Radstake T.R., Boes M. Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol. 2015; (11): 483–92.
14. McGonagle D., McDermott M.F. A proposed classification of the immunological diseases. PLoS Med. 2006; (3): e297.
15. Ozen S., Demirkaya E., Amaryan G., et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis. 2014; (73): 662–67. DOI: https://doi.org/10.1136/annrheumdis-2012-202708
16. Booty M.G., Chae J.J., Masters S.L., et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 2009; (60): 1851–61.
17. Park H., Bourla A.B., Kastner D.L., et al. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol. 2012; (12): 570–80.
18. Cantarini L., Rigante D., Merlini G., et al. The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum. 2014; (43): 818–23.
19. Tombetti E., Giani T., Brucato A., Cimaz R. Recurrent pericarditis in children and adolescents. Front Pediatr. 2019; (7): 419.
20. Brucato A., Emmi G., Cantarini L., et al. Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Intern Emerg Med. 2018; (4): 475–89.
21. Pankuweit S., Wädlich A., Meyer E., Portig I., Hufnagel G., Maisch B. Cytokine activation in pericardial fluids in different forms of pericarditis. Herz. 2000; 25 (8): 748–54.
22. Risti´c A.D., Pankuweit S., Maksimovi´c R., et al. Pericardial cytokines in neoplastic, autoreactive, and viral pericarditis. Heart Fail Rev. 2013; 18 (3): 345–53.
23. Imazio M., Cecchi E., Demichelis B., Ierna S., et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007; 115: 2739–44.
24. Blank N., Lorenz H.M. Idiopathic pericarditis-an autoinflammatory disease? Curr Rheumatol Rep. 2019; 21 (5): 18.
25. Ammirati E., Bizzi E., Veronese G., et al. Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis. Front Med (Lausanne). 2022; 7 (9): 564. DOI: https://doi.org/10.3389/fmed.2022.838564
26. Imazio M., Lazaros G., Picardi E., Vasileiou P., Carraro M., Tousoulis D., et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovasc Med (Hagerstown). 2016; (17): 263–9.
27. Mauro A.G., Bonaventura A., Vecchié A., et al. The role of NLRP3 inflammasome in pericarditis: potential for therapeutic approaches. JACC Basic Transl Sci. 2021; (6): 137–50.
28. Cantarini L., Lucherini O.M., Frediani B., et al. Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes. Int J Immunopathol Pharmacol. 2011; 24 (4): 827–36.
29. Sánchez-Félix M., Burke M., Chen H.H., Patterson C., et al. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge. Adv Drug Deliv Rev. 2020; 167: 66–77. DOI: https://doi.org/10.1016/j.addr.2020.05.009
30. Scott I.C., Hajela V., Hawkins P.N., Lachmann H.J. A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. J Cardiol Cases. 2011; 4 (2): e93–7.
31. Finetti M., Insalaco A., Cantarini L., Meini A., et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr 2014; 164 (6): 1425–31e1.
32. Dagan A., Langevitz P., Shoenfeld Y., Shovman O. Anakinra in idiopathic recurrent pericarditis refractory to immunosuppressive therapy; a preliminary experience in seven patients. Autoimmun Rev. 2019; 18 (6): 627–31.
33. Imazio M., Andreis A., De Ferrari G.M.S., et al. Anakinra for corticosteroid-dependent and colchicineresistant pericarditis: the IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol. 2019; 15: 2047487319879534.
34. Goletti D., Petrone L., Ippolito G., et al. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther. 2018; 16 (6): 501–12. DOI: https://doi.org/10.1080/14787210.2018.1483238
35. Myachikova V.Y., Maslyanskiy A.L., Moiseeva O.M., et al. Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results. J Am Coll Cardiol. 2023; 82 (1): 30–40. DOI: https://doi.org/10.1016/j.jacc.2023.04.046
36. Kineret (anakinra). URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/anakamg111401LB.pdf (date of access 8 January 2024)
37. Kaiser C., Knight A., Nordstrom D., et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int. 2012; 32 (2): 295–9. DOI: https://doi.org/10.1007/s00296-011-2096-3
38. Vila A.T., Puig L., Fernandez-Figueras M.T., et al. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Br J Dermatol. 2005; 153 (2): 417–23.
39. Cabral V.P., Andrade C.A., Passos S.R., Martins M.F., Hokerberg Y.H. Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies. Rev Bras Reumatol Engl Ed. 2016; 56 (6): 543–50.
40. Imazio M., Brucato A., Lazaros G., et al. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality. J Cardiovasc Med (Hagerstown). 2020; (21): 625–9.
41. Tanriover M.D., Akar S., Turkcapar N., Karadag O., et al. Vaccination recommendations for adult patients with rheumatic diseases. Eur J Rheumatol. 2016; 3 (1): 29–35.
42. Klein A., Cremer P., Kontzias A., Furqan M., Forsythe A., Crotty C., Lim-Watson M., Magestro M. Clinical Burden and Unmet Need in Recurrent Pericarditis: A Systematic Literature Review. Cardiol Rev. 2022; 30 (2): 59–69. DOI: https://doi.org/10.1097/CRD.0000000000000356